In a deal that could earn the Cambridge, Mass.-based pharmaceutical company over $1.03 billion, Merrimack Pharmaceuticals (NSDQ:MACK) said yesterday that it is selling its liposome injection cancer drugs, Onivyde and generic Doxil, to Ipsen (EPA:IPN). Merrimack is also slashing its employee headcount down to just 80 people, after laying off 22% of its 400 employees […]
Immunotherapy
Penn State researchers use immune cells to deliver cancer drugs
Researchers from the Penn State Materials Research Institute have developed a biodegradable and photoluminescent nanoparticle that are carried by immune cells to target melanoma. The team’s work was published last week in the journal Small. “The traditional way to deliver drugs to tumors is to put the drug inside some type of nanoparticle and inject those […]
Provectus axes CEO Culpepper for expense account violations
Provectus Biopharmaceuticals Inc. (OTCQB:PVCT) said this week that its board of directors voted unanimously to terminate CEO and chief operating officer Peter Culpepper, after an internal investigation revealed that Culpepper violated the company’s expense account reimbursement policy. The Knoxville, Tenn.-based company said it has established a search committee and is actively seeking a new CEO. […]
Researchers develop nanodiscs to deliver personalized cancer therapy
Researchers from the University of Michigan have developed nanodiscs that deliver a customized therapeutic vaccine to treat colon and melanoma cancer in mice. The team’s work was published in Nature Materials. “We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” senior author James Moon said […]
Bristol-Myers, PsiOxus land licensing agreement
Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]
Researchers use gold nanoparticles to deliver hepatitis C vaccine
Researchers at Brigham & Women’s Hospital have developed electrically activated gold nanoparticles that can bore holes into cells’ outer membranes and allow DNA, RNA and proteins to pass through carrying their cargo. The team’s work was published in Advanced Functional Materials. The team tested its technique using a DNA vaccine against hepatitis C in a mice model. […]
Rewired immune cells respond as targeted cancer therapy
Researchers from Northwestern University have developed a method to rewire immune cells by genetically modifying the cells to sense molecules secreted by tumors and respond by activating the immune system. The team’s work is described in a study published this month in Nature Chemical Biology. Although immunotherapy is growing in popularity among cancer researchers, tumors secrete […]
Orchard Therapeutics, UCLA land $20m for stem cell clinical trial
Orchard Therapeutics and researchers from the University of California Los Angeles Broad Stem Cell Research have been awarded $20 million from the California Institute for Regenerative Medicine’s governing to fund a clinical trial for adenosine deaminase deficiency. The rare, inherited disorder is caused by mutations in a gene that encodes for adenosine deaminase. This results […]
Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU
Immunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the EU. Orphan drug designation is granted to medicines intended for disease with a prevalence no greater than 5 in 10,000 people. According to the Nova Scotia-based company, ovarian cancer affects 3 per 10,000 […]
Topical immunotherapy combo effective against early skin cancer
Researchers from the Washington University School of Medicine and Harvard Medical School have shown that a combination of 2 topical drugs can trigger an immune response against precancerous skin lesions. The study was published yesterday in The Journal of Clinical Investigation. The 2 drugs, calcipotriol and 5-fluorouracil, have been in use for years – topical 5-fluorouracil is […]